The estimated Net Worth of Daniel Lynch is at least $7.32 Million dollars as of 19 June 2020. Mr. Lynch owns over 1,312 units of Bluebird bio Inc stock worth over $72,879 and over the last 10 years he sold BLUE stock worth over $6,546,812. In addition, he makes $695,690 as Independent Chairman of the Board at Bluebird bio Inc.
Daniel has made over 43 trades of the Bluebird bio Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 1,312 units of BLUE stock worth $761 on 19 June 2020.
The largest trade he's ever made was selling 32,500 units of Bluebird bio Inc stock on 28 June 2017 worth over $1,634,100. On average, Daniel trades about 2,955 units every 24 days since 2014. As of 19 June 2020 he still owns at least 125,654 units of Bluebird bio Inc stock.
You can see the complete history of Mr. Lynch stock trades at the bottom of the page.
Daniel S. Lynch serves as Independent Chairman of the Board of the Company. Mr. Lynch is a Class II director who has served as Chairman of our Board of Directors since May 2011. Since October 2007, Mr. Lynch has advised and served as Executive Chair or member of the Board of Directors for a number of private biopharmaceutical companies, which include Stromedix, Inc. (until its acquisition by Biogen Idec in February 2012), Avila Therapeutics, Inc. (until its acquisition by Celgene Corporation in February 2012), Edimer Pharmaceuticals, and Ember Therapeutics, Inc., Nimbus Therapeutics (formerly known as Nimbus Discovery, LLC), and Proclara Biosciences, Inc. He currently serves as Executive Chair or member of the Board of Directors of Blueprint Medicines Corporation (NASDAQ: BPMC), Sesen Bio, Inc. (formerly known as Eleven Biotherapeutics, Inc.) (NASDAQ: SESN), Surface Oncology, Inc. (NASDAQ: SURF), Translate Bio, Inc. (NASDAQ: TBIO), private company SpringWorks Therapeutics, and formerly for BIND Biosciences, Inc. (NASDAQ: BIND). Mr. Lynch joined Third Rock Ventures, L.P., or Third Rock, as an entrepreneur-in-residence in May 2011, and became a Venture Partner in May 2013, and now he is a Senior Advisor. Previously, Mr. Lynch served as Chief Executive and Chief Financial Officer of ImClone Systems Corporation, or ImClone. As ImClone’s Chief Executive Officer, he led ImClone through a significant turnaround, helping to restore the company’s reputation and to secure FDA approval of ERBITUX (Cetuximab), a novel cancer treatment. As its Chief Financial Officer, Mr. Lynch led negotiations to form the major partnership between ImClone and Bristol-Myers Squibb. Earlier in his career, he served in various financial positions at Bristol-Myers Squibb over a 15-year tenure. Mr. Lynch received his B.A. in mathematics from Wesleyan University and his M.B.A. from the Darden Graduate School of Business Administration at the University of Virginia.
As the Independent Chairman of the Board of Bluebird bio Inc, the total compensation of Daniel Lynch at Bluebird bio Inc is $695,690. There are 8 executives at Bluebird bio Inc getting paid more, with Nick Leschly having the highest compensation of $13,153,600.
Daniel Lynch is 62, he's been the Independent Chairman of the Board of Bluebird bio Inc since 2011. There are 1 older and 20 younger executives at Bluebird bio Inc. The oldest executive at Bluebird bio Inc is Wendy Dixon, 64, who is the Independent Director.
Daniel's mailing address filed with the SEC is C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD, CT, 06902.
Over the last 11 years, insiders at Bluebird bio Inc have traded over $130,743,125 worth of Bluebird bio Inc stock and bought 6,469 units worth $399,874 . The most active insiders traders include Steven Gillis, John Maraganore, and Robert I Tepper. On average, Bluebird bio Inc executives and independent directors trade stock every 8 days with the average trade being worth of $6,033. The most recent stock trade was executed by Thomas J Klima on 3 June 2024, trading 3,834 units of BLUE stock currently worth $3,719.
we are leading the gene therapy revolution. our integrated product platforms encompass gene therapy, cancer immunotherapy and gene editing – providing us with the potential to treat, and hopefully cure, a broad range of serious diseases. we have a lot of energy, and it’s not just the abundance of coffee that keeps us going. find out what sparks our excitement and inspires us every day.
Bluebird bio Inc executives and other stock owners filed with the SEC include: